Document Detail

Hormonal contraception and risk of endometrial cancer: a systematic review.
MedLine Citation:
PMID:  20870686     Owner:  NLM     Status:  MEDLINE    
More than 15 case-control studies and at least four large cohort studies demonstrated a decrease in the risk of endometrial cancer of about 50% for ever use of combined oral contraceptives (COCs). In most of these studies, this protective effect persisted for more than 10-15-20 years after cessation of the COC. An increasing protective effect with longer duration of COC use has been found in most studies. The beneficial effect was independent of the composition of COC, i.e. dosage and type of progestogen, combined with ethinyl estradiol 30-50  μg/day. COCs with higher progestogen potency seem to be somewhat more effective. Nonhormonal uterine devices have also been found to be strongly protective; however, data on oral or injectable progestogen-only preparations (POPs) including the levonorgestrel-releasing intrauterine system (LNG-IUS) are still rare, but also suggest similar protective action. COCs, POPs, as well as LNG-IUS can effectively reduce endometrial hyperplasia but should only be used in exceptional cases in patients with or after endometrial cancer. In contrast to nonhormonal IUS, systemic side effects cannot be excluded with LNG-IUS, but they are certainly rare, as the main effect has decreased the endometrial estrogen response because of the high endometrial tissue levels of LNG.
Alfred O Mueck; Harald Seeger; Thomas Rabe
Related Documents :
1622126 - Interrelation between western type cancers and non-western type cancers as regards thei...
755956 - The prevention of endometrial cancer in postmenopausal women with progestogens.
20113256 - Matrix metalloproteinase-7 (mmp-7) polymorphism is a risk factor for endometrial cancer...
21635906 - Flavonoids: potential wnt/beta-catenin signaling modulators in cancer.
18000806 - Cancer in appalachia, 2001-2003.
7226076 - Estradiol receptors in subpopulations of breast cancer cells isolated from human primar...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-09-23
Journal Detail:
Title:  Endocrine-related cancer     Volume:  17     ISSN:  1479-6821     ISO Abbreviation:  Endocr. Relat. Cancer     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-09-27     Completed Date:  2011-01-07     Revised Date:  2011-04-20    
Medline Journal Info:
Nlm Unique ID:  9436481     Medline TA:  Endocr Relat Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  R263-71     Citation Subset:  IM    
Department of Endocrinology and Menopause, Centre for Women's Health BW, University Women's Hospital, Calwer Strasse 7, D-72076 Tuebingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Contraceptives, Oral, Hormonal / administration & dosage*
Endometrial Neoplasms / epidemiology*,  etiology
Risk Factors
Reg. No./Substance:
0/Contraceptives, Oral, Hormonal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A survey of older Hong Kong people's perceptions of telecommunication technologies and telecare devi...
Next Document:  European Palliative Care Research collaborative pain guidelines. Central side-effects management: wh...